[ad_1] Aurobindo Pharma’s Bone Treatment Drug Shows Promise in Tests Aurobindo Pharma’s subsidiary, CuraTeQ Biologics, has announced successful trial results for its new bone treatment medicine. The drug, called BP16, is a copy of an existing medicine called denosumab. The company tested the drug on 204 healthy volunteers, comparing it with Prolia — the original […]
US FDA ends pre-approval inspection of Aurobindo Pharma’s Eugia Steriles with 5 observations – CNBC TV18
[ad_1] Hyderabad-based Aurobindo Pharma Ltd on Tuesday (February 18) announced the completion of the US FDA pre-approval inspection (PAI) at Eugia Steriles Private Ltd, a 100% step-down subsidiary, located in Parawada Mandal, Andhra Pradesh. The inspection took place from February 10-18. Company Value Change %Change “The United States Food and Drug Administration (US FDA) conducted […]
Aurobindo Pharma arm secures UK MHRA approval for bevacizumab biosimilar Bevqolva – CNBC TV18
[ad_1] Drug maker Aurobindo Pharma Ltd on Saturday (December 21) said its step-down subsidiary CuraTeQ Biologics s.r.o. has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Bevqolva, its biosimilar version of bevacizumab. Company Value Change %Change “…CuraTeQ Biologics s.r.o., a step-down subsidiary of the Company has obtained marketing authorisation […]
Aurobindo Pharma’s API unit in Telangana gets 2 US FDA observations – CNBC TV18
[ad_1] Pharmaceutical company Aurobindo Pharma Ltd on Tuesday (December 17) announced that the United States Food and Drug Administration (FDA) completed an inspection of Unit-V, an active pharmaceutical ingredient (API) manufacturing facility of its wholly-owned subsidiary, Apitoria Pharma Private Ltd. Company Value Change %Change “The United States Food and Drug Administration (US FDA) inspected Unit-V, […]
Aurobindo Pharma arm CuraTeQ gets European body’s nod for filgrastim biosimilar – CNBC TV18
[ad_1] Aurobindo Pharma Ltd on Friday (December 13) announced that its wholly-owned subsidiary, CuraTeQ Biologics Private Ltd, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Zefylti (BP13), a filgrastim biosimilar. Company Value Change %Change “…the Committee for Medicinal Products for Human […]